MXPA02007184A - Proteinas que comprenden regiones conservadas de antigenos de superficie nhha de neisseria meningitidis. - Google Patents

Proteinas que comprenden regiones conservadas de antigenos de superficie nhha de neisseria meningitidis.

Info

Publication number
MXPA02007184A
MXPA02007184A MXPA02007184A MXPA02007184A MXPA02007184A MX PA02007184 A MXPA02007184 A MX PA02007184A MX PA02007184 A MXPA02007184 A MX PA02007184A MX PA02007184 A MXPA02007184 A MX PA02007184A MX PA02007184 A MXPA02007184 A MX PA02007184A
Authority
MX
Mexico
Prior art keywords
proteins
neisseria meningitidis
surface antigen
nhha
conserved regions
Prior art date
Application number
MXPA02007184A
Other languages
English (en)
Inventor
Ian Richard Anselm Peak
Original Assignee
Univ Queensland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Queensland filed Critical Univ Queensland
Publication of MXPA02007184A publication Critical patent/MXPA02007184A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se proporcionan proteinas nuevas que constituyen formas modificadas de un antigeno de superficie de Neisseria meningitidis y acidos nucleicos que las codifican. Las proteinas de superficie modificada estan caracterizadas por tener deleciones de aminoacidos no-conservados, y por eso son capaces de ocasionar respuestas inmunes cruzadas-protectoras contra Neisseria meningitidis. La invencion se extiende al uso de los antigenos de superficie modificados en diagnosticos, en vacunas profilacticas y terapeuticas y en el diseno y/o busqueda de medicamentos. Los antigenos de superficie modificados son particularmente utiles en vacunas la cuales inmunizan eficazmente contra un espectro amplio de cepas de Neisseria meningitidis tanto como seria esperado de un correspondiente antigeno de superficie de tipo silvestre.
MXPA02007184A 2000-01-25 2001-01-25 Proteinas que comprenden regiones conservadas de antigenos de superficie nhha de neisseria meningitidis. MXPA02007184A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17791700P 2000-01-25 2000-01-25
PCT/AU2001/000069 WO2001055182A1 (en) 2000-01-25 2001-01-25 PROTEINS COMPRISING CONSERVED REGIONS OF NEISSERIA MENINGITIDIS SURFACE ANTIGEN NhhA

Publications (1)

Publication Number Publication Date
MXPA02007184A true MXPA02007184A (es) 2004-02-26

Family

ID=22650445

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02007184A MXPA02007184A (es) 2000-01-25 2001-01-25 Proteinas que comprenden regiones conservadas de antigenos de superficie nhha de neisseria meningitidis.

Country Status (18)

Country Link
US (4) US7947291B2 (es)
EP (2) EP1252182B1 (es)
JP (3) JP2003523208A (es)
KR (1) KR100698561B1 (es)
CN (2) CN1419564A (es)
AU (1) AU2818101A (es)
BR (1) BR0107857A (es)
CA (1) CA2398139A1 (es)
CZ (1) CZ304379B6 (es)
ES (1) ES2389719T3 (es)
HU (1) HUP0300696A3 (es)
IL (2) IL150822A0 (es)
MX (1) MXPA02007184A (es)
NO (1) NO332229B1 (es)
NZ (1) NZ520445A (es)
PL (1) PL216780B1 (es)
WO (1) WO2001055182A1 (es)
ZA (1) ZA200206153B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1047784E (pt) * 1998-01-14 2009-12-21 Novartis Vaccines & Diagnostic Antigénios de neisseria meningitidis
BR9910089A (pt) 1998-05-01 2004-06-08 Chiron Corp Composições e antìgenos de neisseria meningitidis
ES2397918T3 (es) * 1999-04-30 2013-03-12 Novartis Vaccines And Diagnostics S.R.L. Antígenos Neisseriales conservados
CN100338218C (zh) * 1999-05-19 2007-09-19 启龙股份公司 组合式奈瑟球菌组合物
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
CN1419564A (zh) * 2000-01-25 2003-05-21 昆士兰大学 包含脑膜炎奈瑟氏球菌表面抗原NhhA的保守区域的蛋白质
EP2270030B1 (en) * 2000-02-28 2012-05-23 Novartis Vaccines and Diagnostics S.r.l. Heterologous expression of Neisserial proteins
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
GB0220199D0 (en) * 2002-08-30 2002-10-09 Univ Utrecht Mutant protein and refolding method
TWI360424B (en) * 2002-08-02 2012-03-21 Glaxosmithkline Biolog Sa Vaccine
PT1549338E (pt) 2002-10-11 2011-02-23 Novartis Vaccines & Diagnostic Vacinas polipeptídicas para protecção alargada contra linhagens meningocócicas hipervirulentas
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
WO2007042326A2 (en) * 2005-10-14 2007-04-19 Intercell Ag Neisseria meningitidis antigens
JP5275983B2 (ja) 2006-06-12 2013-08-28 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
JP2012512240A (ja) 2008-12-17 2012-05-31 ノバルティス アーゲー ヘモグロビン受容体を含む髄膜炎菌ワクチン
US20120070458A1 (en) 2009-03-24 2012-03-22 Novartis Ag Adjuvanting meningococcal factor h binding protein
WO2010109324A1 (en) 2009-03-24 2010-09-30 Novartis Ag Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
WO2011024071A1 (en) 2009-08-27 2011-03-03 Novartis Ag Adjuvant comprising aluminium, oligonucleotide and polycation
NZ622048A (en) 2009-08-27 2015-10-30 Novartis Ag Hybrid polypeptides including meningococcal fhbp sequences
CN102724988B (zh) 2009-09-30 2014-09-10 诺华股份有限公司 脑膜炎球菌fHBP多肽的表达
BR112012010531A2 (pt) 2009-10-27 2019-09-24 Novartis Ag "polipeptídeos de modificação meningocócica fhbp"
EP2544713A1 (en) 2010-03-10 2013-01-16 GlaxoSmithKline Biologicals S.A. Immunogenic composition
JP2013522177A (ja) 2010-03-11 2013-06-13 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム グラム陰性細菌性、例えば髄膜炎菌性の感染または疾患に対する免疫原性組成物またはワクチン
CN102802662A (zh) 2010-03-18 2012-11-28 诺华有限公司 用于脑膜炎球菌血清组b的含佐剂疫苗
AU2011268507B2 (en) 2010-06-25 2014-08-14 Novartis Ag Combinations of meningococcal factor H binding proteins
EP2598521A4 (en) * 2010-07-30 2014-03-19 Univ Griffith RECOMBINANT NEISSERIA MENINGITIDIS-POR-A-PORIN PROTEINS
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
WO2012032498A2 (en) 2010-09-10 2012-03-15 Novartis Ag Developments in meningococcal outer membrane vesicles
WO2012054879A1 (en) * 2010-10-22 2012-04-26 Duke University Compositions and methods for the treatment of septic arthritis, osteomyelitis, and bacteremia
US20150147356A1 (en) 2011-05-12 2015-05-28 Alan Kimura Antipyretics to enhance tolerability of vesicle-based vaccines
CA2862247A1 (en) 2011-12-29 2013-07-04 Novartis Ag Adjuvanted combinations of meningococcal factor h binding proteins
AU2013214105A1 (en) 2012-02-02 2014-07-24 Novartis Ag Promoters for increased protein expression in meningococcus
ES2750366T3 (es) 2012-03-08 2020-03-25 Glaxosmithkline Biologicals Sa Ensayo de potencia in vitro para vacunas meningocócicas basadas en proteína
CN104602704B (zh) 2012-06-14 2019-08-06 诺华股份有限公司 针对血清组x脑膜炎球菌的疫苗
CA2882619A1 (en) 2012-09-06 2014-03-13 Novartis Ag Combination vaccines with serogroup b meningococcus and d/t/p
SG11201606478YA (en) 2014-02-28 2016-09-29 Glaxosmithkline Biolog Sa Modified meningococcal fhbp polypeptides
CN110214022A (zh) 2016-11-25 2019-09-06 葛兰素史密丝克莱恩生物有限公司 免疫原性缀合物及其用途
BR112019010625A2 (pt) 2016-11-25 2019-10-22 Glaxosmithkline Biologicals Sa conjugado imunogênico, processo para preparar o conjugado imunogênico, nomv-ligante intermediário, usos do mesmo e de nomv, composição imunogênica, e, vacina.
WO2024178355A1 (en) * 2023-02-24 2024-08-29 BioNTech SE Systems and methods for engineering synthetic antigens to promote tailored immune responses

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4843000A (en) 1979-12-26 1989-06-27 Syntex (U.S.A.) Inc. Simultaneous calibration heterogeneous immunoassay
US4849338A (en) 1982-07-16 1989-07-18 Syntex (U.S.A.) Inc. Simultaneous calibration heterogeneous immunoassay
US4550081A (en) 1980-05-19 1985-10-29 The Board Of Trustees Of The Leland Stanford Jr. University Non-reverting salmonella
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0273116A3 (en) * 1986-10-09 1990-05-02 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Gonococcal and meningococcal polypeptides, vaccines and diagnostics
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5785973A (en) 1988-02-01 1998-07-28 Praxis Biologics, Inc. Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
WO1989009385A1 (fr) 1988-03-24 1989-10-05 Zach, Johann Dispositif manometrique ou dynamometrique
EP0449958B9 (en) * 1988-12-19 2003-05-28 American Cyanamid Company Meningococcal class 1 outer-membrane protein vaccine
WO1992001813A1 (en) 1990-07-25 1992-02-06 Syngene, Inc. Circular extension for generating multiple nucleic acid complements
US5422252A (en) 1993-06-04 1995-06-06 Becton, Dickinson And Company Simultaneous amplification of multiple targets
US5646259A (en) 1995-03-24 1997-07-08 St. Louis University DNA encoding haemophilus adhesion proteins
US6143495A (en) 1995-11-21 2000-11-07 Yale University Unimolecular segment amplification and sequencing
GB9611673D0 (en) * 1996-06-05 1996-08-07 Peptide Therapeutics Ltd Meningococcal vaccine
EP1900818A3 (en) 1997-11-06 2008-06-11 Novartis Vaccines and Diagnostics S.r.l. Neisserial antigens
GB9726398D0 (en) * 1997-12-12 1998-02-11 Isis Innovation Polypeptide and coding sequences
PT1047784E (pt) 1998-01-14 2009-12-21 Novartis Vaccines & Diagnostic Antigénios de neisseria meningitidis
BR9910089A (pt) 1998-05-01 2004-06-08 Chiron Corp Composições e antìgenos de neisseria meningitidis
GB9810276D0 (en) 1998-05-13 1998-07-15 Smithkline Beecham Biolog Novel compounds
WO2000061165A1 (en) * 1999-04-13 2000-10-19 Smithkline Beecham Corporation Conserved adhesin motif and methods of use thereof
ES2397918T3 (es) 1999-04-30 2013-03-12 Novartis Vaccines And Diagnostics S.R.L. Antígenos Neisseriales conservados
WO2000066791A1 (en) * 1999-04-30 2000-11-09 Chiron Corporation Neisseria genomic sequences and methods of their use
GB9916529D0 (en) * 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
CN1419564A (zh) * 2000-01-25 2003-05-21 昆士兰大学 包含脑膜炎奈瑟氏球菌表面抗原NhhA的保守区域的蛋白质
TWI360424B (en) * 2002-08-02 2012-03-21 Glaxosmithkline Biolog Sa Vaccine
US7628995B2 (en) * 2003-12-23 2009-12-08 Glaxosmithkline Biologicals S.A. Outer membrane vesicles and uses thereof

Also Published As

Publication number Publication date
CZ304379B6 (cs) 2014-04-09
JP2012051902A (ja) 2012-03-15
KR100698561B1 (ko) 2007-03-21
PL356819A1 (en) 2004-07-12
BR0107857A (pt) 2002-10-29
US20090068216A1 (en) 2009-03-12
NO20023487D0 (no) 2002-07-22
EP2395013A3 (en) 2012-03-21
NZ520445A (en) 2004-02-27
EP1252182A1 (en) 2002-10-30
US8367070B2 (en) 2013-02-05
EP1252182A4 (en) 2005-03-02
NO332229B1 (no) 2012-08-06
KR20020065938A (ko) 2002-08-14
HUP0300696A2 (hu) 2003-07-28
US20020160016A1 (en) 2002-10-31
CN1419564A (zh) 2003-05-21
JP2014024849A (ja) 2014-02-06
ES2389719T3 (es) 2012-10-30
JP2003523208A (ja) 2003-08-05
US20090068229A1 (en) 2009-03-12
IL150822A0 (en) 2003-02-12
HUP0300696A3 (en) 2004-10-28
US7947291B2 (en) 2011-05-24
CN102417537A (zh) 2012-04-18
EP2395013A2 (en) 2011-12-14
US8383790B2 (en) 2013-02-26
IL150822A (en) 2011-06-30
PL216780B1 (pl) 2014-05-30
NO20023487L (no) 2002-09-24
CZ20022482A3 (cs) 2003-01-15
ZA200206153B (en) 2003-11-03
EP1252182B1 (en) 2012-06-20
AU2818101A (en) 2001-08-07
CA2398139A1 (en) 2001-08-02
WO2001055182A1 (en) 2001-08-02
US20130136762A1 (en) 2013-05-30

Similar Documents

Publication Publication Date Title
MXPA02007184A (es) Proteinas que comprenden regiones conservadas de antigenos de superficie nhha de neisseria meningitidis.
WO2004030608A3 (en) Nanoemulsion vaccines
WO2003028632A3 (en) Development of a preventive vaccine for filovirus infection in primates
EP1170368A3 (en) Immunization by inoculation of dna transcription unit
GB2434367A (en) Improved vaccines
NZ331651A (en) BSW17 peptide immunogens for vaccination against and treatment of allergy
WO2003059381A3 (en) Immunogenic preparations and vaccines on the basis of mrna
WO2007056266A3 (en) Cd40 ligand fusion protein vaccine
WO2004014418A3 (en) Neisserial vaccine compositions comprising a combination of antigens
WO2002074795A3 (en) Oligomeric complexes of chimeric proteins with enhanced immunogenic potential
NO20015073D0 (no) Vaksiner
GB0123580D0 (en) Vaccine
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
PT1326633E (pt) Composição compreendendo micropartículas imunogénicas
WO2003066094A3 (en) Hepatitis b vaccines
ES2177927T3 (es) Composicion para provocar una reaccion inmunologica a un determinante antigenico no proteinico.
WO2000012535A3 (en) Neisseria meningitidis polypeptide, nucleic acid sequence and uses thereof
HK1056830A1 (en) Mannose as intranasal vaccine adjuvant
WO2003049765A3 (en) Enveloped virus vaccine and method for production
WO2003083083A3 (en) Methods of using flt3-ligand in immunization protocols
WO2001063278A3 (en) Antigenic fragments associated with stress-induced proteins and their use as vaccines
WO2004078099A3 (en) Compositions and methods for the generation of protective immune response against malaria
WO2005012538A3 (en) Accelerated vaccination
TNSN08184A1 (en) Chimeric antigens and vaccines
WO2000006198A3 (en) Adjuvant comprising pulmonary surfactant

Legal Events

Date Code Title Description
FG Grant or registration